OBJECTIVES: To investigate the possibility of culturing dendritic cells (DCs) and cytokine-induced killer (CIK) cells, obtained at initial diagnosis of AML in elderly patients, and to investigate the safety and efficacy of treatment with autologous DCs and CIK cells when administered to these patients in combination with low-dose chemo therapy. METHODS: DCs and CIK cells obtained at initial diagnosis of AML in elderly patients were cultured and used in combination with low-dose chemo therapy to treat these patients (immunotherapy group). Elderly patients with AML treated only with low-dose chemotherapy served as the control. Before treatment and on day 7 after treatment with autologous DCs and CIK cells, T cell subsets and cytokine levels were evaluated in the immunotherapy group. RESULTS: A total of 21 elderly patients with AML were included in the immunotherapy group and 23 in the control group. The clinical efficacy in the immunotherapy group was greater than in the control group. The percentages of T cell subsets and cytokine levels after immunotherapy treatment were significantly higher than before the treatment. CONCLUSION: Immuno therapy with autologous DCs and CIK cells was found to be a promising candidate for treatment of AML in elderly patients.
AppelbaumFRGundackerHHeadDR: Age and acute myeloid leukemia. Blood2006; 107: 3481–3485.
2.
EsteyE: Acute myeloid leukaemia and myelodysplastic syndromes in older patients. J Clin Oncol2007; 25: 1908–1915.
3.
FerrantiniMCaponeIMarincolaFM: International meeting “Immunotherapy of cancer: challenges and needs”. Cancer Immunol Immunother2007; 56: 581–585.
4.
ThanendrarajanSNowakMAbkenH: Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: more than one plus one. Leuk Res2011; 35: 1136–1142.
5.
LeiZZhangGMHongM: Fusion of dendritic cells and CD34+CD38− acute myeloid leukaemia (AML) cells potentiates targeting AML-initiating cells by specific CTL induction. J Immunother2009; 32: 408–414.
6.
LinnYCLauLCHuiKM: Generation of cytokine-induced killer cells from leukaemic samples with in vitro cytotoxicity against autologous and allogeneic leukaemic blasts. Br J Haematol2002; 116: 78–86.
7.
OliosoPGiancolaRDi RitiM: Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: A pilot clinical trial. Hematol Oncol2009; 27: 130–139.
8.
ZhaoQZhangHLiY: Anti-tumour effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro. J Exp Clin Cancer Res2010; 29: 118.
9.
LiuPChenLHuangX: The antitumour effects of CIK cells combined with docetaxel against drug-resistant lung adenocarcinoma cell line SPC-A1/DTX in vitro and in vivo. Cancer Biother Radiopharm2009; 24: 91–98.
10.
SangioloDMesianoGCarnevale-SchiancaF: Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumour after hematopoietic cell transplantation. Expert Opin Biol Ther2009; 9: 831–840.
11.
MaggioRPeragineNCalabreseE: Generation of functional dendritic cells (DC) in adult acute lymphoblastic leukemia: rationale for a DC-based vaccination program for patients in complete hematological remission. Leuk Lymphoma2007; 48: 302–310.
12.
VardimanJMThieleJArberDA: The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukaemia: rationale and important changes. Blood2009; 114: 937–951.
13.
KöhlerTPlettigRWetzsteinW: Cytokine-driven differentiation of blasts from patients with acute myelogenous and lymphoblastic leukemia into dendritic cells. Stem Cells2000; 18: 139–147.
14.
SchmetzerHMKremserALoiblJ: Quantification of ex vivo generated dendritic cells (DC) and leukemia-derived DC contributes to estimate the quality of DC, to detect optimal DC-generating methods or to optimize DC-mediated T-cell-activation-procedures ex vivo or in vivo. Leukemia2007; 21: 1338–1341.
15.
KremserADressigJGrabruckerC: Dendritic cells (DCs) can be successfully generated from leukemic blasts in individual patients with AML or MDS: an evaluation of different methods. J Immunother2010; 33: 185–199.
16.
YatesJWChalmerBMcKegneyFP: Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer1980; 45: 2220–2224.
17.
GuLFZhangWGWangFX: Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukaemia. J Cancer Res Clin Oncol2011; 137: 997–1003.
18.
RobsonNCHovesSMaraskovskyE: Presentation of tumour antigens by dendritic cells and challenges faced. Curr Opin Immunol2010; 22: 137–144.
19.
LiLReinhardtPSchmittA: Dendritic cells generated from acute myeloid leukaemia (AML) blasts maintain the expression of immunogenic leukaemia associated antigens. Cancer Immunol Immunother2005; 54: 685–693.
20.
CarusoDAFraserSHardyK: Costimulation molecule expression and subset distribution of blood dendritic cells in normal children and newly diagnosed pediatric leukaemia and lymphoma patients. Exp Hematol2008; 36: 1691–1703.
21.
KitawakiTKadowakiNFukunagaK: Cross-priming of CD8+ T cells in vivo by dendritic cells pulsed with autologous apoptotic leukemic cells in immunotherapy for elderly patients with acute myeloid leukaemia. Exp Hematol2011; 39: 424–433.e2.
22.
NiamMLinnYCChongS Fook: Clinical scale expansion of cytokine-induced killer cells is feasible from healthy donors and patients with acute and chronic myeloid leukemia at various stages of therapy. Exp Hematol2011; 39: 897–903.e1.
23.
Schmidt-WolfIGBlumeKGJohnstonV: Propagation of large numbers of T cells with natural killer cell markers. Br J Haematol1994; 87: 453–458.
24.
MohtyMIsnardonDBlaiseD: Identification of precursors of leukemic dendritic cells differentiated from patients with acute myeloid leukaemia. Leukaemia2002; 16: 2267–2274.
25.
LinnYCWangSMHuiKM: Comparative gene expression profiling of cytokine-induced killer cells in response to acute myeloid leukemic and acute lymphoblastic leukemic stimulators using oligonucleotide arrays. Exp Hematol2005; 33: 671–681.
26.
ZhongRTengJHanB: Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immunother2011; 60: 1497–1502.
